StockNASDAQ · US · USDHealthcare · Medical Devices
$GEHC
GE HealthCare Technologies Inc.
GE HealthCare is a healthcare technology and diagnostics company serving hospitals, health systems, researchers, and other public, private, academic, and government institutions in over 160 countries. Headquartered in Chicago, Illinois, it sells medical devices, consumable products, services, and AI-enabled cloud and software solutions. Its business has four segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. Imaging includes molecular imaging, CT, MR, women’s health, and X-ray systems, related software, and services. Advanced Visualization Solutions offers specialized ultrasound and procedural guidance products and digital tools. Patient Care Solutions supplies monitoring, diagnostic cardiology, maternal and infant care, anesthesia, consumables, and digital applications. Pharmaceutical Diagnostics develops and produces contrast media and radiopharmaceuticals, as well as contrast injection devices offered through third-party collaborations. GE HealthCare also provides equipment maintenance, training, data integration, and other service offerings.
GE HealthCare (GEHC) received FDA clearance for Critical Care Suite 3.0, AI software detecting feeding tubes on X-rays. Testing showed 99.2% sensitivity and 91.6% mean DICE localization. No prior-period comparison was provided, according to the company.
GE HealthCare is expanding its global collaborations to study the Photonova Spectra photon-counting CT system. Keio University, Centro Cardiologico Monzino, Universitätsspital Zürich, University of Wisconsin-Madison, and Stanford Medicine will explore its applications in cardiovascular imaging, coronary CT angiography, and other clinical uses. Researchers aim to optimize imaging protocols, assess diagnostic performance, and reduce radiation doses.
GE HealthCare (GEHC) launched the MAGNUS Neuro Alliance to advance neuroscience research using its MRI technology. The alliance includes leading institutions and aims to develop imaging biomarkers for neurological conditions. GEHC stock has declined 2.2% since the announcement. The global functional/brain MRI market is projected to grow at 8% CAGR through 2031, according to Markets and Markets.
via TradingView
GEHC sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning GEHC (GE HealthCare Technologies Inc.). Coverage has skewed bullish: 6 bullish, 2 neutral, and 0 bearish.
Recent GEHC coverage spans regulation, technology and financial news.
What's driving GEHC
FDA clearance reduces regulatory friction for GEHC’s on-device X-ray AI in critical care, supporting incremental adoption expectations.
The alliance is a strategic partnership that may boost long‑term demand for GEHC's ultra‑high‑gradient MRI systems, but the immediate market reaction was negative.
AlphAI scores every news story that mentions GEHC with an AI model for sentiment and relevance, and aggregates insider trades from GE HealthCare Technologies Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
GE HealthCare (GEHC) received FDA clearance for Critical Care Suite 3.0, AI software detecting feeding tubes on X-rays. Testing showed 99.2% sensitivity and 91.6% mean DICE localization. No prior-period comparison was provided, according to the company.
GE HealthCare is expanding its global collaborations to study the Photonova Spectra photon-counting CT system. Keio University, Centro Cardiologico Monzino, Universitätsspital Zürich, University of Wisconsin-Madison, and Stanford Medicine will explore its applications in cardiovascular imaging, coronary CT angiography, and other clinical uses. Researchers aim to optimize imaging protocols, assess diagnostic performance, and reduce radiation doses.
GE HealthCare (GEHC) launched the MAGNUS Neuro Alliance to advance neuroscience research using its MRI technology. The alliance includes leading institutions and aims to develop imaging biomarkers for neurological conditions. GEHC stock has declined 2.2% since the announcement. The global functional/brain MRI market is projected to grow at 8% CAGR through 2031, according to Markets and Markets.
InspireMD (NSPR) received FDA approval for its TCAR stent, while Eli Lilly (LLY) and Bayer (BAYRY) secured approvals for obesity and stroke drugs. Johnson & Johnson (JNJ) won FDA approval for a head and neck cancer treatment. Meanwhile, Sionna (SION), Nano-X (NNOX), and Coherus (CHRS) announced workforce reductions. Pfizer (PFE) and Blackstone agreed to co-fund an obesity drug. Key stock prices were reported.
Wall Street analysts are generally bullish on GE HealthCare (GEHC), with 11 'Strong Buy' ratings. Argus raised its price target to $110, maintaining a 'Buy' rating. The mean target is $87.87, a 6.8% premium over the current price, and the highest target suggests 33.6% upside.
GE HealthCare Technologies Inc. added AI-assisted Lung Guidance and AutoAS to its Vscan Air handheld ultrasound system, aiding lung and aortic stenosis assessments. The stock gained 4.2% since the Nov. 3 announcement, with a market cap of $37.25 billion. The tools aim to improve point-of-care diagnostics and could enhance the company's market position.
The U.S. Supreme Court requested the Trump administration's input on an appeal from pharmaceutical and medical-device companies, including AstraZeneca, Roche, GE HealthCare, Johnson & Johnson, Pfizer, and Viatris, seeking to halt a lawsuit accusing them of funding terrorism in Iraq. The lawsuit alleges the companies paid bribes to secure contracts, with the money going to a militant group. The companies argue the allegations lack sufficient connection to terrorism and intent.
GE Healthcare (GEHC) launched AI tools for its Vscan Air handheld ultrasound, available in the U.S. and select markets. UBS raised its price target on GEHC to $80 from $73, maintaining a Neutral rating. Chief Science and Technology Officer Taha Kass-Hout will resign in December 2026.
GE HealthCare Technologies' Chief Science and Technology Officer, Taha Kass-Hout, will resign effective December 31, 2026. The company did not disclose the reason or a replacement. This news was reported in an SEC filing on November 5, 2026.
GE HealthCare Technologies Inc. (GEHC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 4, 2026, Taha Kass-Hout notified GE HealthCare Technologies Inc. (“GE HealthCare”) that he will resign as Chief